Diseases /
Fallopian Tube Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A carcinoma arising from the fallopian tube. Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas. [1]
Fallopian tube carcinomas most frequently harbor alterations in TP53, NOTCH3, CCNE1, BRD4, and SMARCA4 [2].
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 8 Mutation, and TP53fs are the most common alterations in fallopian tube carcinoma [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for fallopian tube carcinoma, 4 are FDA-approved in at least one setting and 3 have NCCN guidelines in at least one setting [3].
Niraparib +
Disease is predicted to be sensitive: -
Olaparib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Maintenance therapy (FDA, NCCN) |
| Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy. |
Rucaparib +
Disease is predicted to be sensitive: -
Bevacizumab + Olaparib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Maintenance therapy (FDA) |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Clinical Trials
There are 190 clinical trials for fallopian tube carcinoma, of which 147 are open and 43 are completed or closed. Of the trials that contain fallopian tube carcinoma as an inclusion criterion, 4 are early phase 1 (4 open), 72 are phase 1 (47 open), 35 are phase 1/phase 2 (29 open), 61 are phase 2 (50 open), 1 is phase 2/phase 3 (1 open), 15 are phase 3 (14 open), and 2 are phase 4 (2 open).
BRCA1, BRCA2, and BARD1 are the most frequent gene inclusion criteria for fallopian tube carcinoma clinical trials [3].
Paclitaxel, carboplatin, and olaparib are the most common interventions in fallopian tube carcinoma clinical trials.
Significant Genes in Fallopian Tube Carcinoma
ARID1A +
ARID1A is altered in 5.45% of fallopian tube carcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 3 clinical trials for fallopian tube carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain ATM status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
ATR +
ATR is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ATR status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain BARD1 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
BRCA1 +
BRCA1 is altered in 3.64% of fallopian tube carcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 29 clinical trials for fallopian tube carcinoma, of which 22 are open and 7 are closed. Of the trials that contain BRCA1 status and fallopian tube carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 10 are phase 2 (6 open), 5 are phase 3 (4 open), and 2 are phase 4 (2 open) [3].
Olaparib, bevacizumab, niraparib, and rucaparib have evidence of efficacy in patients with BRCA1 mutation in fallopian tube carcinoma [3].
BRCA2 +
BRCA2 is altered in 1.82% of fallopian tube carcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 29 clinical trials for fallopian tube carcinoma, of which 22 are open and 7 are closed. Of the trials that contain BRCA2 status and fallopian tube carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 10 are phase 2 (6 open), 5 are phase 3 (4 open), and 2 are phase 4 (2 open) [3].
Olaparib, bevacizumab, niraparib, and rucaparib have evidence of efficacy in patients with BRCA2 mutation in fallopian tube carcinoma [3].
BRIP1 +
BRIP1 is altered in 1.82% of fallopian tube carcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain BRIP1 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain C11orf30 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
CDK12 +
CDK12 is altered in 3.64% of fallopian tube carcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain CDK12 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CDK4 +
CDK4 is altered in 1.89% of fallopian tube carcinoma patients [2].
CDK4 is an inclusion eligibility criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain CHEK1 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain CHEK2 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
EGFR +
EGFR is altered in 4.76% of fallopian tube carcinoma patients [2].
EGFR is an inclusion eligibility criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC3 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
ERCC4 +
ERCC4 is altered in 3.03% of fallopian tube carcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC4 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
ERCC5 +
ERCC5 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC5 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
ERCC6 +
ERCC6 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC6 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
FANCA +
FANCA is altered in 1.82% of fallopian tube carcinoma patients [2].
FANCA is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCA status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCB status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCC status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCD2 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCE +
FANCE is altered in 4.55% of fallopian tube carcinoma patients [2].
FANCE is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCE status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCF status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCG +
FANCG is altered in 4.0% of fallopian tube carcinoma patients [2].
FANCG is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCG status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCI status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain FANCL status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain FANCM status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HDAC1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HDAC2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 5 clinical trials for fallopian tube carcinoma, of which 2 are open and 3 are closed. Of the trials that contain MCPH1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
MDM2 +
MDM2 is altered in 1.82% of fallopian tube carcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MDM4 +
MDM4 is altered in 1.82% of fallopian tube carcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MLH1 +
MLH1 is altered in 1.67% of fallopian tube carcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH3 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain MRE11A status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MSH6 +
MSH6 is altered in 3.64% of fallopian tube carcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH6 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
MUTYH +
MUTYH is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MUTYH status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain NBN status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].
NPM1 +
NPM1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain PALB2 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
POLE +
POLE is altered in 1.82% of fallopian tube carcinoma patients [2].
POLE is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
PPP2R1A +
PPP2R1A is altered in 1.89% of fallopian tube carcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R1A status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 3 clinical trials for fallopian tube carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PPP2R2A status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 4 (1 open) [3].
PTEN +
PTEN is altered in 1.59% of fallopian tube carcinoma patients [2].
PTEN is an inclusion eligibility criterion in 5 clinical trials for fallopian tube carcinoma, of which 2 are open and 3 are closed. Of the trials that contain PTEN status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain RAD50 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
RAD51 +
RAD51 is altered in 1.82% of fallopian tube carcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain RAD51 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD51B status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD51C status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD51D status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
RAD54L +
RAD54L is altered in 3.03% of fallopian tube carcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain RAD54L status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [3].
SLX4 +
SLX4 is altered in 3.33% of fallopian tube carcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain SLX4 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [3].
SMARCB1 +
SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
STAG2 +
STAG2 is altered in 3.64% of fallopian tube carcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STAG2 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
STK11 +
STK11 is altered in 1.59% of fallopian tube carcinoma patients [2].
STK11 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STK11 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
TP53 +
TP53 is altered in 87.3% of fallopian tube carcinoma patients [2].
TP53 is an inclusion eligibility criterion in 3 clinical trials for fallopian tube carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
XRCC1 +
XRCC1 is an inclusion eligibility criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain XRCC1 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
